, Article L5122-6 of the French Public Health Code
, Regulation (EC) 1394/2007 on advanced therapy medicinal products, OJ, vol.324, pp.121-137
, /23/EC on tissues and cells (OJ L102/48-58), or the Directive 2002/98/EC on human blood and blood components, vol.33, pp.30-40, 2004.
, The Regulation also allows SMEs a 90% reduction in the fees (and other applicants a 65% reduction in the fee) that would otherwise be payable to the EMA for scientific advice
,
, Marketing authorizations for Provenge, Chondrocelect, MACI and Glybera were withdrawn at the request of the marketing authorization holders
, , p.197, 2017.
Les unités de thérapie cellulaire à l'épreuve de la règlementation sur les médicaments de thérapie innovante, p.576, 2014. ,
Adaptive pathways" to drug authorisation: adapting to industry?, pp.354-4437, 2016. ,
, , 2014.
Les nouveaux enjeux de la politique pharmaceutique européenne: pour des produits de santé sûrs, 2019. ,
, , 2011.
Payers' views of the changes arising through the possible adoption of Adaptive Pathways, Front. Pharmacol, p.7, 2016. ,
The voice of rare disease patients in Europe, Early access to medicines in Europe: Compassionate use to become a reality, p.2017 ,
The institutional and methodological politics of valuation and payment for regenerative medicine products in the UK, New Genetics and Society, 2018. ,
, The Law and Regulation of Medicines, 2008.
Dealing with uncertainty and high prices of new medicines: a comparative analysis of the use of managed entry agreements in, Soc. Sci. Med, p.124, 2015. ,
Managed entry agreements for pharmaceuticals: the European experience, EMiNet, 2013. ,
Are there specific translational challenges in regenerative medicine? Lessons from other fields, Regenerative Medicine, issue.7, p.885, 2015. ,
, Medicinal Product Liability and Regulation, 2013.
, Pharmaceutical Medicine, Biotechnology and European Law, 2001.
The EU pharmaceutical markets: parameters and pathways, Health Systems Governance in Europe: the role of EU Law and Policy, p.635, 2010. ,
European Union Health Law, 2015. ,
Research Handbook in EU Health Law and Policy, 2017. ,
, , 2012.
Le monopole pharmaceutique et son avenir, (Cahier de Droit de la Santé juridiques, 2017. ,
UK calls for ban of parallel trade of prescription medicines -what are the EU competition law implications?, European Competition Law Review, vol.34, issue.4, 2013. ,
La promotion de l'innovation en matière de santé: quelles logiques à l'oeuvre dans l'Union européenne?, vol.627 ,
Reimbursement of cell-based regenerative therapy in the UK and France, Medical Law Review, vol.24, issue.2, p.234, 2016. ,
The legal landscape for Advanced Therapy Medicinal Products: material and institutional implementation of European Union rules, Journal of Law and Society, vol.39, issue.1, 2012. ,
The European Medicines Agency: a public health European agency?, Medicine and Law Journal, vol.25, issue.1, p.31, 2012. ,
URL : https://hal.archives-ouvertes.fr/hal-01560579
, Droit français et européen, 2018.
, Regulatory challenges in the drug-food continuum, IMI Stakeholder Forum, 2017.
Electronic health data for postmarket surveillance: a vision not realized'(2015) 38 Drug Saf, p.26025018 ,
Constitutional Asymmetry and Pharmaceutical Policy-Making in the European Union, Journal of European Public Policy, vol.12, issue.4, 2005. ,
Regulating Medicines in Europe: the European Medicines Agency, Marketing Authorisation, Transparency and Pharmacovigilance, p.6, 2006. ,
, Clinical Medicine, vol.87
EU law and policy on pharmaceuticals marketing and post-market control including product liability, p.156, 2017. ,
Limiting pharmaceutical parallel trade in the European Union: regulatory and economic justifications, European Law Review, vol.36, issue.3, p.385, 2011. ,